Showing results (41-50 of 65) with videos related to
Sort By:
Pageof 7
Blood|March 25, 2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaThierry Facon, Christopher P Venner, Nizar J Bahlis, et al.Lancet (London, England)|August 13, 2021
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 studySaad Z Usmani, Alfred L Garfall, Niels W C J van de Donk, et al.Future Oncology (London, England)|May 3, 2023
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myelomaPhilippe Moreau, Niels Wcj van de Donk, Hareth Nahi, et al.Lancet (London, England)|October 9, 2007
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialThierry Facon, Jean Yves Mary, Cyrille Hulin, et al.Blood|January 25, 2002
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trialPhilippe Moreau, Thierry Facon, Michel Attal, et al.Leukemia|January 2, 2022
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIAThierry Facon, Gordon Cook, Saad Z Usmani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2016
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyélomeBruno Royer, Stéphane Minvielle, Momar Diouf, et al.Blood|January 16, 2013
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02Xavier Leleu, Michel Attal, Bertrand Arnulf, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2017
Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyPhilippe Moreau, Michel Attal, Denis Caillot, et al.Pageof 7